Cleveland Clinic 29th Annual Diabetes Therapeutics, Technology and Surgery
Cleveland Clinic’s world class facultyhas designed the 29th Annual Diabetes Therapeutics, Technology and Surgery to provide up-to-date reviews of relevant research and treatment strategies for Type 1 and 2 diabetes. Participation should increase practitioners’ competence and clinical performance treatment of diabetes and its complications, which should lead to better patient outcomes. Physicians, diabetes educators, nurses, nurse practitioners, pharmacists and physician assistants will all benefit from the lessons learned throughout this activity. Worth 7 AMA PRA Category I Credits™. Accreditation also provided by the ANCC, AAPA and ACPE with NO POST TEST. Additionally, physicians can earn up to 7 ABIM MOC points for this activity.
Cost: $99.00Add to cart
Key Features
Updated strategies for Types 1 & 2 Diabetes and complications. 7 AMA PRA Category I Credits™ and ABIM MOC.
Topics Covered
Therapeutic options to manage both Type 1 and 2 diabetes, the importance of maintaining muscle mass during obesity management, insulin pump technology, new roles and complications for GLP1 receptor agonists, SGLT-2 inhibitors and mineralocorticoid receptor agonists, glucose variability, effects of high fat and high protein diets, GLP-1’s impact on sleep apnea, nutritional supplements and much more.
Learning Objectives
Upon completion of this activity, the participant will be able to:
1. Critically appraise clinical evidence and guidelines supporting hybrid closed-loop systems in pregnancy and identify key considerations when initiating and monitoring hybrid closed-loop pumps during pregnancy.
2. Describe the efficacy of inhaled insulin to insulin pump therapy in diabetes management.
3. Discuss the role of nutritional supplements in the management of Type 2 diabetes and glycemic control, including the use of berberine.
4. Discuss future directions and challenges in developing and implementing oral GLP-1 agonists and multi-agonist therapy in diabetes care and summarize clinical evidence on the incidence and risk of gastroparesis, pancreatitis, and thyroid cancer associated with GLP-1 agonist use.
5. Analyze current research and define treatment strategies for challenges in diabetes care, including dementia, blood pressure, including intensive blood pressure control and both cardiovascular and renal complications in diabetes.
6. Discuss evidence-based treatment strategies for post-gastric bypass hypoglycemia, including dietary modifications, pharmacotherapy and other interventions.
7. Discuss practical considerations for initiating and titrating novel therapies such as efsitora alfa in different patient populations, including those with complex diabetes management needs.
Target Audience
This activity is designed for physicians, diabetes educators, nurses, nurse practitioners, pharmacists, pharmacy technicians, physician assistants, residents and fellows, and other health care professionals who care for patients with diabetes.
Additional credit info
American Medical Association (AMA)
Cleveland Clinic Center for Continuing Education designates this live activity for a maximum of 7.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Participants claiming CME credit from this activity may submit the credit hours to the American Osteopathic Association for Category 2 credit.
American Nurses Credentialing Center (ANCC)
Cleveland Clinic Center for Continuing Education designates this live activity for a maximum of 7.75 ANCC contact hours.
American Academy of PAs (AAPA)
Cleveland Clinic Center for Continuing Education has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 7.75 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.
Accreditation Council of Pharmacy Education (ACPE)
Cleveland Clinic Center for Continuing Education designates this knowledge-based activity for a maximum of 7.75 hours. Credit will be provided to NABP CPE Monitor within 60 days after the activity completion.
Universal Activity Number List:
Pharmacist UAN: JA0000192-0000-25-235-L01-P
Technician UAN: JA0000192-0000-25-235-L01-T
Interprofessional Continuing Education (IPCE) Credit
This activity was planned by and for the healthcare team, and learners will receive 7.75 Interprofessional Continuing Education (IPCE) credit for learning and change.
Certificate of Participation
A certificate of participation will be provided to other health care professionals for requesting credits in accordance with their professional boards and/or associations.
American Board of Internal Medicine (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 7.75 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.